{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T05:21:28Z","timestamp":1747200088242,"version":"3.40.5"},"reference-count":38,"publisher":"Media Sphere Publishing House","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["S.S. Korsakov J. Neuro. Psych."],"published-print":{"date-parts":[[2024,4,23]]},"abstract":"<jats:p>Cerebrovascular diseases (CVDs) are one of the leading causes of death and disability In Russia: they rank second in the structure of mortality from diseases of the circulatory system and in the overall mortality of the population. Successful treatment of CVD involves an integrated approach to the problem, taking into account the compensation of cardiovascular disorders, the elimination of neurological and psychopathological syndromes, the improvement of cerebral circulation and the use of neuroprotective agents that increase the resistance of brain tissue to hypoxia and ischemia. Insufficient clinical efficacy of neuroprotectors is due to a number of objective reasons, of which only two are universal. The first of these reasons is the timing of the start of therapy in the clinic, as a rule, is outside the \u00abtherapeutic window\u00bb; the second reason is the fact that disturbance of the patency of the cerebral vessels in the affected area makes it difficult or impossible to deliver the drug to the penumbra area. The way out of this situation is the intranasal route of drug administration, which is characteristic for the analogs of regulatory peptides such as for H-Met-Glu-His-Phe-Pro-Gly-Pro-OH (MGHPPGP). The review of clinical studies indicates that MGHPPGP is clinically effective in the treatment of ischemic stroke both in the acute period of stroke and in the recovery period. The clinical efficacy of MGHPPGP was shown both in atherothrombotic and cardioembolic subtypes of stroke, against the background of blood flow disturbances in both the carotid and vertebrobasilar systems.<\/jats:p>","DOI":"10.17116\/jnevro202412408256","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T05:09:45Z","timestamp":1724303385000},"page":"56","source":"Crossref","is-referenced-by-count":0,"special_numbering":"Vyp. 2","title":["Place of oligopeptide H-Met-Glu-His-Phe-Pro-Gly-Pro-OH in the therapy and rehabilitation of patients with ischemic stroke"],"prefix":"10.17116","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9078-589X","authenticated-orcid":false,"given":"N.N.","family":"Spirin","sequence":"first","affiliation":[{"name":"Yaroslavl State Medical University","place":["Yaroslavl, Russia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1296-1861","authenticated-orcid":false,"given":"V.N.","family":"Fedorov","sequence":"additional","affiliation":[{"name":"Yaroslavl State Medical University","place":["Yaroslavl, Russia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6739-6154","authenticated-orcid":false,"given":"V.P.","family":"Vdovichenko","sequence":"additional","affiliation":[{"name":"Educational Institution Grodno State Medical University","place":["Grodno, Belarus"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6743","reference":[{"doi-asserted-by":"publisher","key":"key-10.17116\/jnevro202412408256-1","DOI":"10.14412\/2074-2711-2017-2-15-24"},{"doi-asserted-by":"publisher","key":"key-10.17116\/jnevro202412408256-2","DOI":"10.1007\/s11055-020-00997-w"},{"doi-asserted-by":"publisher","key":"key-10.17116\/jnevro202412408256-3","DOI":"10.1016\/j.soin.2018.06.008"},{"doi-asserted-by":"publisher","key":"key-10.17116\/jnevro202412408256-4","DOI":"10.1161\/CIRCRESAHA.116.308426"},{"doi-asserted-by":"publisher","key":"key-10.17116\/jnevro202412408256-5","DOI":"10.1042\/CS20160607"},{"unstructured":"Ischemic stroke and transient ischemic attack in adults. Clinical guidelines. M. 2022. (In Russ.)","key":"key-10.17116\/jnevro202412408256-6"},{"doi-asserted-by":"publisher","key":"key-10.17116\/jnevro202412408256-7","DOI":"10.1592\/phco.30.pt2.62S"},{"doi-asserted-by":"publisher","key":"key-10.17116\/jnevro202412408256-8","DOI":"10.33029\/9704-5782-5-STR2-2020-1-288"},{"unstructured":"Tanashyan MM, Barkhatov DYu. Metabolic therapy in neurology: new approaches. RMJ. 2012;8:406. (In Russ.)","key":"key-10.17116\/jnevro202412408256-9"},{"doi-asserted-by":"publisher","key":"key-10.17116\/jnevro202412408256-10","DOI":"10.1155\/2017\/4863079"},{"doi-asserted-by":"publisher","key":"key-10.17116\/jnevro202412408256-11","DOI":"10.4062\/biomolther.2017.018"},{"doi-asserted-by":"publisher","key":"key-10.17116\/jnevro202412408256-12","DOI":"10.21518\/2079-701X-2019-1-24-30"},{"doi-asserted-by":"publisher","key":"key-10.17116\/jnevro202412408256-13","DOI":"10.3171\/2017.1.FOCUS16522"},{"doi-asserted-by":"publisher","key":"key-10.17116\/jnevro202412408256-14","DOI":"10.17816\/brmma12268"},{"unstructured":"Cerebral neuroprotection: rescue and recovery: based on the results of the World Stroke Congress 2008. Zdorovije Ukrainy. 2008;11:10-12. (In Russ.)","key":"key-10.17116\/jnevro202412408256-15"},{"doi-asserted-by":"publisher","key":"key-10.17116\/jnevro202412408256-16","DOI":"10.1134\/S1819712412020080"},{"unstructured":"Ashmarin IP, Nezavibatko VN, Myasoedov NF, et al. Nootropic analogue of adrenocorticotropin 4-10 \u2014 Semax (15 years of experience in development and study). Jurnal vyschej nervnoy dejatelnosti. 1997;47:419-425. (In Russ.)","key":"key-10.17116\/jnevro202412408256-17"},{"doi-asserted-by":"crossref","unstructured":"Zolotarev YA Dadayan AK, Dolotov OV, et al. Peptides uniformly labeled with tritium in studies of their degradation in vivo and in vitro. Bioorganicheskaya Himiya. 2006;32(2):80-88. (In Russ.)","key":"key-10.17116\/jnevro202412408256-18","DOI":"10.1134\/S1068162006020099"},{"doi-asserted-by":"publisher","key":"key-10.17116\/jnevro202412408256-19","DOI":"10.1134\/S1068162006010055"},{"unstructured":"Levitskaya NG, Glazova NY, Sebentsova EA, et al. Investigation of the spectrum of physiological activity of the ACTH4-10 analogue of the heptapeptide semax. Neirokhimiya. 2008;25(1):111-118. (In Russ.)","key":"key-10.17116\/jnevro202412408256-20"},{"doi-asserted-by":"publisher","key":"key-10.17116\/jnevro202412408256-21","DOI":"10.1007\/s11055-012-9562-6"},{"doi-asserted-by":"publisher","key":"key-10.17116\/jnevro202412408256-22","DOI":"10.1134\/S1819712420040121"},{"unstructured":"Zarubina IV. Peptide neuroprotection. Pod red. Dyakonov M.M., Kamensky A.A. SPb.: Nauka; 2009. (In Russ.)","key":"key-10.17116\/jnevro202412408256-23"},{"doi-asserted-by":"crossref","unstructured":"Dubynina EV, Dolotov OV, Transcription factor CREB and processes of memory formation. Neirokhimiya. 2009;26(3):181-190. (In Russ.)","key":"key-10.17116\/jnevro202412408256-24","DOI":"10.1134\/S1819712409030015"},{"doi-asserted-by":"publisher","key":"key-10.17116\/jnevro202412408256-25","DOI":"10.1016\/j.brainres.2006.07.108"},{"unstructured":"Aubekova OM, Klimova EA. Therapeutic efficacy of \u00abSemax 1%\u00bb in ischemic stroke of varying severity.Vestnik nevrilogii, psychiatrii i neurochirurgii. 2015;2:41-47. (In Russ.)","key":"key-10.17116\/jnevro202412408256-26"},{"unstructured":"The use of peptide neuroprotector and nootropic \u00abSemax 1%\u00bb in the first hours and days of acute cerebral stroke. Ed. Skvortsova V.I. M. 2011;31. (In Russ.)","key":"key-10.17116\/jnevro202412408256-27"},{"unstructured":"Tsukurova LA, Baroyan KM, Torgashov AN. Efficacy and safety of the Semax1% neuroprotector in patients with acute cerebrovascular accident at various hospitalization periods. Bulleten Neurologii, Psychiatrii and Neurohirutgii. 2013;4:71-75. (In Russ.)","key":"key-10.17116\/jnevro202412408256-28"},{"unstructured":"Tsukurova LA. Study of the efficacy and safety of the neuroprotector \u00abSemax 1%\u00bb in patients with ischemic stroke of varying severity. Prakt. medicina. 2013;66(1):242-244. (In Russ.)","key":"key-10.17116\/jnevro202412408256-29"},{"unstructured":"Zaets TY, Potapova AA, Rudneva VV, et al. The use of the drug Semax 0.1% in the early recovery period of ischemic stroke. Kremlevskaya medecina. Klinicheskiy vestnik. 2001;2:61-63. (In Russ.)","key":"key-10.17116\/jnevro202412408256-30"},{"unstructured":"Ivanova NE. The results of the use of Semax in cognitive impairment in the acute period of ischemic stroke and in chronic cerebral ischemia. Effective Pharmacotherapy. 2012;2:2-8. (In Russ.)","key":"key-10.17116\/jnevro202412408256-31"},{"doi-asserted-by":"crossref","unstructured":"Kotsyubinskaya YV, Kazakov AV, Safonova NY. Influence of Semax on the emotional state and cognitive processes in patients with ischemic stroke in the acute period. Medical Alphabet. 2019;24(3):38-41. (In Russ.)","key":"key-10.17116\/jnevro202412408256-32","DOI":"10.33667\/2078-5631-2019-3-24(399)-40-44"},{"unstructured":"Polyakova AV. Neuroprotective therapy outside the \u00abtherapeutic window\u00bb: the possibilities of Semax. Bulleten Neurologii, Psychiatrii and Neurohirurgii. 2014;5:54-60. (In Russ.)","key":"key-10.17116\/jnevro202412408256-33"},{"unstructured":"Potapova AA. Complex treatment of ischemic strokes with the use of neuropeptide drugs. Kremlevskaya medecina. Klinicheskiy vestnik. 2003;2:34-39. (In Russ.)","key":"key-10.17116\/jnevro202412408256-34"},{"unstructured":"Shmonin AA, Verbitskaya EV, Solovieva LN, et al. Meta-analysis: the effectiveness of Semax in the acute period of ischemic stroke. Vestnik vosstanovitelnoy mediciny. 2018;2:81-88. (In Russ.)","key":"key-10.17116\/jnevro202412408256-35"},{"doi-asserted-by":"publisher","key":"key-10.17116\/jnevro202412408256-36","DOI":"10.17116\/jnevro20181183261-68"},{"unstructured":"Kostenko EV, Eneeva MA. Complex therapy of patients in the early recovery period of cerebral stroke: the effectiveness of the use of neuropeptide metabolic drugs (Semax). Medical Alphabet. 2015;12(253):37-45. (In Russ.)","key":"key-10.17116\/jnevro202412408256-37"},{"unstructured":"Tereshin AE, Kiryanova VV, Ivanova NE, et al. functions in patients with cerebral stroke. Russ. Neurohirurg. Jurnal im. Prof. A.L. Polenov. 2019;11(1):53-60. (In Russ.)","key":"key-10.17116\/jnevro202412408256-38"}],"container-title":["S.S. Korsakov Journal of Neurology and Psychiatry"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T05:44:11Z","timestamp":1745387051000},"score":1,"resource":{"primary":{"URL":"https:\/\/mediasphera.ru\/issues\/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova-2\/2024\/8-2\/1199772982024082056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,23]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,21]]}},"alternative-id":["10.17116\/jnevro202412408256"],"URL":"https:\/\/doi.org\/10.17116\/jnevro202412408256","relation":{},"ISSN":["1997-7298"],"issn-type":[{"type":"print","value":"1997-7298"}],"subject":[],"published":{"date-parts":[[2024,4,23]]}}}